These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

180 related articles for article (PubMed ID: 9207420)

  • 41. Consolidation with alemtuzumab improves progression-free survival in patients with chronic lymphocytic leukaemia (CLL) in first remission: long-term follow-up of a randomized phase III trial of the German CLL Study Group (GCLLSG).
    Schweighofer CD; Ritgen M; Eichhorst BF; Busch R; Abenhardt W; Kneba M; Hallek M; Wendtner CM
    Br J Haematol; 2009 Jan; 144(1):95-8. PubMed ID: 19016732
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Signaling molecules and cytokine production in T cells of patients with B-cell chronic lymphocytic leukemia: long-term effects of fludarabine and alemtuzumab treatment.
    Kiaii S; Choudhury A; Mozaffari F; Rezvany R; Lundin J; Mellstedt H; Osterborg A
    Leuk Lymphoma; 2006 Jul; 47(7):1229-38. PubMed ID: 16923551
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Campath-1H.
    Sorokin P
    Clin J Oncol Nurs; 2001; 5(2):65-6. PubMed ID: 11899778
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Experience with alemtuzumab in treatment of chronic lymphocytic leukaemia in the Netherlands.
    Laros-van Gorkom BA; Huisman CA; Wijermans PW; Schipperus MR
    Neth J Med; 2007 Oct; 65(9):333-8. PubMed ID: 17954952
    [TBL] [Abstract][Full Text] [Related]  

  • 45. [Campath-1H--a monoclonal antibody for treatment of non-Hodgkin's and chronic lymphatic leukemia].
    de Nully Brown P; Hansen MM; Nissen NI
    Ugeskr Laeger; 1997 Jul; 159(28):4389-93. PubMed ID: 9235735
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment with campath-1H for relapsed chronic lymphocytic leukemia after allogeneic peripheral blood stem cell transplantation does not abrogate the development of chronic GVHD.
    Wolff D; Steiner B; Stilgenbauer S; Kahl C; Leithäuser M; Junghanss C; Wilhelm S; Kleine HD; Zimmermann R; Hartung G; Casper J; Freund M
    Eur J Haematol; 2004 Feb; 72(2):145-8. PubMed ID: 14962253
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Alemtuzumab-induced remission of both severe paraneoplastic pemphigus and leukaemic bone marrow infiltration in a case of treatment-resistant B-cell chronic lymphocytic leukaemia.
    Hohwy T; Bang K; Steiniche T; Peterslund NA; d'Amore F
    Eur J Haematol; 2004 Sep; 73(3):206-9. PubMed ID: 15287918
    [TBL] [Abstract][Full Text] [Related]  

  • 48. A personal history of the CAMPATH-1H antibody.
    Waldmann H
    Med Oncol; 2002; 19 Suppl():S3-9. PubMed ID: 12180490
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Campath-1H in B-chronic lymphocytic leukemia: report on a patient treated thrice in a 3 year period.
    Pangalis GA; Dimopoulou MN; Angelopoulou MK; Tsekouras CH; Siakantaris MP
    Med Oncol; 2000 Feb; 17(1):70-3. PubMed ID: 10713664
    [TBL] [Abstract][Full Text] [Related]  

  • 50. The PNH phenotype cells that emerge in most patients after CAMPATH-1H therapy are present prior to treatment.
    Rawstron AC; Rollinson SJ; Richards S; Short MA; English A; Morgan GJ; Hale G; Hillmen P
    Br J Haematol; 1999 Oct; 107(1):148-53. PubMed ID: 10520035
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Subcutaneous alemtuzumab in fludarabine-refractory chronic lymphocytic leukemia: clinical results and prognostic marker analyses from the CLL2H study of the German Chronic Lymphocytic Leukemia Study Group.
    Stilgenbauer S; Zenz T; Winkler D; Bühler A; Schlenk RF; Groner S; Busch R; Hensel M; Dührsen U; Finke J; Dreger P; Jäger U; Lengfelder E; Hohloch K; Söling U; Schlag R; Kneba M; Hallek M; Döhner H;
    J Clin Oncol; 2009 Aug; 27(24):3994-4001. PubMed ID: 19597025
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Campath-1H monoclonal antibody therapy.
    Flynn JM; Byrd JC
    Curr Opin Oncol; 2000 Nov; 12(6):574-81. PubMed ID: 11085457
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Heterogeneous CD52 expression among hematologic neoplasms: implications for the use of alemtuzumab (CAMPATH-1H).
    Rodig SJ; Abramson JS; Pinkus GS; Treon SP; Dorfman DM; Dong HY; Shipp MA; Kutok JL
    Clin Cancer Res; 2006 Dec; 12(23):7174-9. PubMed ID: 17145843
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Chronic lymphocytic leukemia: current and emerging treatment approaches.
    Kay NE; Rai KR; O'Brien S
    Clin Adv Hematol Oncol; 2006 Nov; 4(11 Suppl 22):1-10; quiz 11-2. PubMed ID: 17143256
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Treatment of refractory chronic lymphocytic leukemia with Campath-1H in combination with lamivudine in chronic hepatitis B infection.
    Heider U; Fleissner C; Zavrski I; Jakob C; Dietzel T; Eucker J; Ockenga J; Possinger K; Sezer O
    Eur J Haematol; 2004 Jan; 72(1):64-6. PubMed ID: 14962266
    [TBL] [Abstract][Full Text] [Related]  

  • 56. In vivo CAMPATH-1H prevents GvHD following nonmyeloablative stem-cell transplantation.
    Kottaridis PD; Milligan DW; Chopra R; Chakraverty RK; Chakrabarti S; Robinson S; Peggs K; Verfuerth S; Pettengell R; Marsh JC; Schey S; Mahendra P; Morgan GJ; Hale G; Waldmann H; Ruiz de Elvira MC; Williams CD; Devereux S; Linch DC; Goldstone AH; MacKinnon S
    Cytotherapy; 2001; 3(3):197-201. PubMed ID: 12171726
    [TBL] [Abstract][Full Text] [Related]  

  • 57. [News in therapeutic management of chronic lymphoid leukemia].
    Michallet AS; Salles G; Coiffier B; Michallet M
    Bull Cancer; 2005 Mar; 92(3):249-56. PubMed ID: 15820919
    [TBL] [Abstract][Full Text] [Related]  

  • 58. In vitro and in vivo evaluation of direct rhenium-188-labeled anti-CD52 monoclonal antibody alemtuzumab for radioimmunotherapy of B-cell chronic lymphocytic leukemia.
    De Decker M; Bacher K; Thierens H; Slegers G; Dierckx RA; De Vos F
    Nucl Med Biol; 2008 Jul; 35(5):599-604. PubMed ID: 18589304
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
    Van Den Neste E; Letestu R; Aurran-Schleinitz T; Ysebaert L; Feugier P; Leprêtre S; Dartigeas C
    Leuk Lymphoma; 2012 Mar; 53(3):362-70. PubMed ID: 21854093
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Acute renal failure and disseminated intravascular coagulation following an idiosyncratic reaction to Alemtuzumab (Campath 1H) or fludarabine.
    Osborne WL; Lennard AL
    Haematologica; 2005 Jan; 90(1):ECR05. PubMed ID: 15653459
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.